title: Late relapses in Hodgkin lymphoma: a clinical and immunohistochemistry study.
abstract: Survival in Hodgkin lymphoma (HL) has significantly increased, and most relapses occur in the first 2 years. We analyzed the proportion of relapses occurring after 5 years, the method of detection, and survival in the database of patients with HL in our hospital (1967-2005). We undertook a retrospective study of clinical and molecular characteristics with the use of 12 different antibodies (Abs): CD30, CD15, CD20, CD3, BCL-2, BCL-6, CD57, EMA, p53, Ki-67, Aurora kinase A, and PAX-5. We studied 534 patients with HD and found 150 relapses (28%), 30 of which occurred 5 years after the end of treatment. The relapses were detected during a scheduled appointment in 16 (54%) asymptomatic patients. Seven of 30 patients relapsed with a different histological type. There were no statistically significant differences in survival between those patients with a late relapse and new remission and those who never relapsed. None of the molecular markers were associated with relapse. Long-term survival was not significantly different in relapsed patients with remission after treatment compared with patients who never relapsed. We need to maintain active follow-up in order to detect late and recoverable relapses.
authors.affiliation: Department of Medical Oncology, University Hospital Puerta de Hierro, Madrid, Spain. mprovenciop@yahoo.es
authors.forename: Mariano
authors.initials: M
authors.lastname: Provencio
authors.forename: Clara
authors.initials: C
authors.lastname: Salas
authors.forename: Isabel
authors.initials: I
authors.lastname: Millán
authors.forename: Blanca
authors.initials: B
authors.lastname: Cantos
authors.forename: Antonio
authors.initials: A
authors.lastname: Sánchez
authors.forename: Carmen
authors.initials: C
authors.lastname: Bellas
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000378:metabolism; D002648:Child; D015331:Cohort Studies; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006689:Hodgkin Disease / Q000378:metabolism / Q000401:mortality / Q000473:pathology*; D006801:Humans; D007124:Immunoenzyme Techniques; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000378:metabolism / Q000401:mortality / Q000473:pathology*; D011379:Prognosis; D012074:Remission Induction; D015996:Survival Rate; D055815:Young Adult
chemical_list: D014408:Biomarkers, Tumor